{"nct_id":"NCT00511459","title":"Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients","status":"COMPLETED","status_verified_date":"2015-10","start_date":"2007-07","start_date_type":null,"primary_completion_date":"2010-08","primary_completion_date_type":"ACTUAL","completion_date":"2014-05","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["AMGN"]}